Amplia Therapeutics Limited (ATX.AX)
Develops cancer and fibrosis drugs targeting a protein called FAK.
0.13+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-43.5%
The outlook
ATX.AX is trading near the lower end of its 52-week range and below both its 50- and 200-day moving averages, reflecting a bearish lean in current sentiment. Analyst targets average roughly 223% above the current price, though coverage appears sparse. The stock sits in a depressed position relative to recent history.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range17% of the way from its 52-week low to high
Price targetAvg target +223% vs current price
Market cap
$66.7M
52-wk high
0.28
52-wk low
0.10
50-day avg
0.13
200-day avg
0.14
Trailing P/E
—